Ocera Therapeutics Upgraded to Outperform at BMO Capital Markets (OCRX)
Ocera Therapeutics (NASDAQ:OCRX) was upgraded by BMO Capital Markets from a “market perform” rating to an “outperform” rating in a research note issued on Monday, TheFlyOnTheWall.com reports.
Ocera Therapeutics (NASDAQ:OCRX) opened at 13.86 on Monday. Ocera Therapeutics has a 1-year low of $2.00 and a 1-year high of $17.50. The stock’s 50-day moving average is $10.99 and its 200-day moving average is $8.59. The company’s market cap is $211.3 million.
Ocera Therapeutics (NASDAQ:OCRX) last released its earnings data on Wednesday, November 13th. The company reported ($0.77) earnings per share (EPS) for the quarter. Analysts expect that Ocera Therapeutics will post $-2.55 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on OCRX. Analysts at Zacks downgraded shares of Ocera Therapeutics to a “neutral” rating in a research note to investors on Wednesday, January 1st. They now have a $13.60 price target on the stock. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Ocera Therapeutics in a research note to investors on Monday, December 30th. They set a “buy” rating and a $19.00 price target on the stock. Finally, analysts at Cowen and Company initiated coverage on shares of Ocera Therapeutics in a research note to investors on Tuesday, December 17th. They set an “outperform” rating on the stock.
Ocera Therapeutics, Inc, formerly Tranzyme, Inc, is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing mechanism-based therapeutics for the treatment of upper gastrointestinal (NASDAQ:OCRX) motility disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.